Daina Graybosch
Stock Analyst at Leerink Partners
(1.13)
# 2,814
Out of 4,667 analysts
116
Total ratings
36.71%
Success rate
-10.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.57 | +75.44% | 8 | May 15, 2024 | |
| TSVT 2seventy bio | Upgrades: Outperform | $5 → $18 | $3.11 | +478.78% | 5 | Jan 31, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $87.22 | -55.29% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $1.00 | +200.00% | 10 | Feb 24, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $120 → $122 | $97.44 | +25.21% | 18 | Feb 3, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $1.26 | +1,011.11% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $2.22 | +350.45% | 7 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $2.72 | +2,105.88% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $1.69 | +433.97% | 10 | Nov 15, 2022 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $40 → $38 | $14.62 | +159.92% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $28 | $1.52 | +1,742.11% | 5 | Sep 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $5.20 | +53.85% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $102.14 | +119.31% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.50 | +1,100.00% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $59 | $7.85 | +651.59% | 7 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.64 | +936.59% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.43 | +529.37% | 4 | Feb 25, 2022 |
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.57
Upside: +75.44%
2seventy bio
Jan 31, 2024
Upgrades: Outperform
Price Target: $5 → $18
Current: $3.11
Upside: +478.78%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $87.22
Upside: -55.29%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $1.00
Upside: +200.00%
Merck & Co.
Feb 3, 2023
Maintains: Outperform
Price Target: $120 → $122
Current: $97.44
Upside: +25.21%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $1.26
Upside: +1,011.11%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $2.22
Upside: +350.45%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $2.72
Upside: +2,105.88%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $1.69
Upside: +433.97%
Arcus Biosciences
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $14.62
Upside: +159.92%
Sep 27, 2022
Maintains: Outperform
Price Target: $25 → $28
Current: $1.52
Upside: +1,742.11%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $5.20
Upside: +53.85%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $102.14
Upside: +119.31%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.50
Upside: +1,100.00%
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $7.85
Upside: +651.59%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.64
Upside: +936.59%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.43
Upside: +529.37%